TITLE

Research & Markets: Kidney Cancer - Pipeline Review, Q1 2011

PUB. DATE
April 2011
SOURCE
Biomedical Market Newsletter;4/30/2011, p938
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the publication of the report titled "Kidney Cancer: Pipeline Review: Q1 2011" by Research & Markets.
ACCESSION #
60669401

 

Related Articles

  • Initial Experience with Temsirolimus in 2nd-, 3rd- and 4th-Line Therapy for Metastatic Renal Cell Cancer: Good Clinical Response. Kuru, Timur Hasan; Huber, Johannes; Hatiboglu, Gencay; Wagener, Nina; Pahernik, Sascha; Hadaschik, Boris; Hohenfellner, Markus // Urologia Internationalis;Apr2011, Vol. 86 Issue 3, p256 

    Purpose: To report our experience with temsirolimus in 2nd-, 3rd- and 4th-line therapy for patients with metastatic renal cell carcinoma (mRCC). Patients and Methods: In our prospectively maintained tumor registry, we identified 6 mRCC patients with temsirolimus in >1st-line systemic therapy....

  • Detection of Rapalog-Mediated Therapeutic Response in Renal Cancer Xenografts Using 64Cu-bevacizumab ImmunoPET. Chang, Albert J.; Sohn, Rebecca; Lu, Zhi Hong; Arbeit, Jeffrey M.; Lapi, Suzanne E. // PLoS ONE;Mar2013, Vol. 8 Issue 3, p1 

    The importance of neovascularization for primary and metastatic tumor growth fostered numerous clinical trials of angiogenesis inhibitors either alone or in combination with conventional antineoplastic therapies. One challenge with the use of molecularly targeted agents has been the...

  • Trials Probe New Agents for Kidney Cancer. Hampton, Tracy // JAMA: Journal of the American Medical Association;7/12/2006, Vol. 296 Issue 2, p155 

    The article reports on new medical trials which are being conducted on the effectiveness of several new medications on kidney cancer. Sunitinib, Temsirolimus, Sorafenib, and bevacizumab are all being examined. The article discusses some of the results from the trials and also some of the...

  • Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma. Gunnarsson, Orvar; Pfanzelter, Nicklas R.; Cohen, Roger B.; Keefe, Stephen M. // Cancer Management & Research;2015, Vol. 7, p65 

    Axitinib is a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor-α, and c-kit. Phase I studies demonstrated 5 mg twice daily as the recommended starting dose with notable effects seen in renal cell carcinoma, an observation...

  • Nivolumab: Various toxicities: 14 case reports.  // Reactions Weekly;7/13/2019, Vol. 1761 Issue 1, p279 

    No abstract available.

  • Does renal cancer cause salty taste? Baker, Stephen T.; M.T. // Cortlandt Forum;3/25/95, Vol. 8 Issue 3, p86 

    Discusses the connection between renal cancer and salty taste on a patient's lips. Sample case; Disappearance of the salty taste after surgery of the tumor.

  • Kidney Cancer. Babaian, Kara N. // AUANews;Oct2019 Supplement Genitourinary Cancer, p15 

    No abstract available.

  • More Trouble Over EU Clinical Trials Rules. O'Donnell, Peter // Applied Clinical Trials;Jan2003, Vol. 12 Issue 1, p21 

    Focuses on the views of health practitioners on the problems associated with the implementation of the European Union directive on clinical trials. Effects of disparate legal regulations on the success of international clinical trials; Details of the protocol amendment procedures and...

  • Study Completion Times.  // Applied Clinical Trials;May2011, Vol. 20 Issue 5, p19 

    The article offers analysis on the study completion times on applied clinical trials of contract research organization or sponsor company of the study in the U.S.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics